“…Danofloxacin, a third-generation synthetic fluoroquinolone developed for use in veterinary medicine, is approved for the treatment of respiratory infections in cattle, chickens, and pigs [9,10]. Danofloxacin reaches a 4-5 times higher concentration in the lung tissue than in the plasma and has activity against most Gram-negative bacteria, such as P. multocida, M. haemolytica, Histophilus somni, and Enterobacterales (Escherichia coli, Klebsiella, and Salmonella), and some Gram-positive bacteria, such as Staphylococcus aureus and Streptococcus pneumoniae [11][12][13][14]. Danofloxacin has a very wide distribution volume in sheep and goats due to having high lipid solubility, low binding to plasma proteins, and being a substrate for ATP-dependent efflux transporters [15,16].…”